CompletedNot Applicable

Alpha Lipoic Acid Effect on No-Reflow Phenomenon

Egypt70 participantsStarted 2022-01-01

Plain-language summary

Prospective, randomized, open-label, controlled clinical trial to evaluate the efficacy and tolerability of Alpha Lipoic Acid administration on oxidative stress, inflammatory markers, clinical outcome and occurrence of No-Reflow in post myocardial infarction (MI) patients by assessment of aldehyde dehydrogenase-2 (ALDH2) as a marker of oxidative stress and paraoxonase-1 (PON-1) as a marker of oxidative stress and inflammation.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Female or male aged \>18
✓. STEMI patients undergoing PCI

Exclusion criteria

✕. Patients with a recent history of myocardial infarction (MI), a previous PCI or a previous coronary artery bypass graft
✕. A late presentation (\>12 h), unsuccessful primary PCI (residual stenosis \>50% in the culprit lesion after procedure)
✕. Pretreatment with thrombolytic or glycoprotein IIb/IIIa inhibitor therapy before primary PCI
✕. Infectious or inflammatory disease
✕. Severe liver or renal disease, (AST or ALT \>3x ULN or Total bilirubin \>2.5 x ULN), (CrCl \< 60 ml/min (based on the Cockroft-Gault equation)
✕. Neoplasm, or hematological disorders
✕. Pregnant or breast-feeding patients
✕. Active participation in another clinical study

What they're measuring

Occurrence of No-Reflow phenomena

Timeframe: During 1 week post PCI

Trial details

NCT IDNCT05360602

SponsorAin Shams University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-07-01

View on ClinicalTrials.gov More No-Reflow Phenomenon trials